Healthcare Professional
Study Overview
Physicians across the United States are offering a unique opportunity to patients with Cognitive Impairment in Schizophrenia. An investigational research study is being conducted and your patients may be eligible to participate.
This is a double-blind, randomized, parallel-group, dose ranging study of the efficacy and safety of oral doses of the investigational medication and placebo on top of an established treatment regimen of either olanzapine, risperidone/paliperidone, quetiapine or aripiprazole monotherapy.
For interested study candidates, it is not necessary to change their already stable antipsychotic medication regimen.
Study participants will attend 18 visits over the course of 35 weeks. Study phases include:
- 2-week screening/run-in phase
- 24-week treatment phase
- 9-week follow-up period
To enroll in the study, potential participants must be:
- 18 to 65 years of age
- diagnosed with schizophrenia at or before the age of 35
- currently taking one of five specific antipsychotic medications for schizophrenia
- considered outpatient
- reading at a fifth grade level or higher
- able to meet additional requirements